-transparent.png){kind=logo}
Sixteen patients with accelerated or blastic phase chronic myelogenous leukemia were treated with high-dose cytosine arabinoside given at 3 g/m2 every 12 h for two to eight doses per course. All patients had an immediate clearing of peripheral blood blast cells. Five patients achieved a complete response for 1-14 months, median 4.5 months. Toxicity was significant and predictable on the basis of dose given. We have identified both an effective and a toxic dosing schedule. The rapid response is dramatic but relatively short-lived, and suggests that additional agents in conjunction with reinfusion of autologous stem cells may offer these patients a greater chance of significant response.
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
August 1988,
Cancer,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
January 2002,
Haematologia,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
January 1985,
Cancer treatment reports,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
July 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
May 1984,
Gan to kagaku ryoho. Cancer & chemotherapy,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
April 1983,
The Tohoku journal of experimental medicine,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
June 1993,
Leukemia & lymphoma,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
January 1985,
Neoplasma,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
August 1988,
Cancer,
T J Ernst, and
D S Rosenthal, and
J D Griffin, and
G P Canellos
August 1987,
Klinische Wochenschrift,
